Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

INTRODUCTION: Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia. This 12-week study evaluated the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Hong, Li, Weimin, Huang, Zhouqing, Han, Yajun, Huang, Xuecheng, Li, Dongye, Xing, Xiaochun, Monsalvo, Maria Laura, Wu, You, Mao, Jackie, Xin, Lily, Chen, Jiyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942644/
https://www.ncbi.nlm.nih.gov/pubmed/36802321
http://dx.doi.org/10.1007/s40119-023-00304-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942644/
https://www.ncbi.nlm.nih.gov/pubmed/36802321
http://dx.doi.org/10.1007/s40119-023-00304-x

Ejemplares similares